Medicines Co. jumped a many in roughly a month after Food and Drug Administration staff endorsed a company’s intravenous blood clotting drug for approval.

The batch rose as most as 6.6 percent following an FDA staff report expelled Monday that pronounced Kengreal should be authorized for patients undergoing procedures to open blocked arteries.

Medicines Co. is seeking Kengreal’s capitulation as an choice to other clot preventers such as clopidogrel, a general chronicle of Bristol-Myers Squibb Co.’s Plavix. Kengreal would be used to revoke a risks of heart conflict and blood clots in patients who’ve had a procession to open a blocked artery and who can’t take a pill.

The batch rose 3.3 percent to $29.25 during 12:26 p.m. in New York, after progressing rising to as most as $30.17.

The FDA had creatively deserted Kengreal in Apr 2014, seeking Medicines Co. to do some-more research of a clinical hearing information and resubmit a drug. In Monday’s report, FDA staff pronounced that a “study as a standalone hearing was sufficient to aver approval.”

A physique of outward advisers to a FDA will accommodate Wednesday to plead either a advantage of Kengreal outweighs a increasing risk of draining compared to clopidogrel. The FDA is scheduled to order on a focus by Jun 23.

Medicines Co.’s biggest product is Angiomax, another anticlotting drug, that sole $636 million final year. The Parsippany, New Jersey-based drugmaker pronounced on Apr 9 that sales of Angiomax could tumble this year if a general chronicle of a drug becomes accessible in a U.S. in June.